{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:41:24Z","timestamp":1793835684815,"version":"4.6.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"DOI":"10.1038\/s41591-026-04674-2","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:02:39Z","timestamp":1790845359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R.","family":"Tuttle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-2947","authenticated-orcid":false,"given":"Petter","family":"Bjornstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1518-9320","authenticated-orcid":false,"given":"Cathy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-1851","authenticated-orcid":false,"given":"Menno","family":"Pruijm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8012-1931","authenticated-orcid":false,"given":"Phillip J.","family":"McCown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Hodgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z. I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Belmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1465-2095","authenticated-orcid":false,"given":"Milenta Mariam","family":"Chacko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0614-0373","authenticated-orcid":false,"given":"Vivek","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4896-5868","authenticated-orcid":false,"given":"Thomas","family":"Idorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Schytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6522-2703","authenticated-orcid":false,"given":"Amaya","family":"Zaratiegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-0582","authenticated-orcid":false,"given":"Matthias","family":"Kretzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"4674_CR1","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic, R. Z., Rooney, M. T. & Tuttle, K. R. Diabetic kidney disease: challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. 12, 2032\u20132045 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"4674_CR2","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMc2207018","volume":"387","author":"KR Tuttle","year":"2022","unstructured":"Tuttle, K. R. et al. Incidence of chronic kidney disease among adults with diabetes, 2015\u20132020. N. Engl. J. Med. 387, 1430\u20131431 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4674_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2011","unstructured":"Kovesdy, C. P. Epidemiology of chronic kidney disease: an update 2022. Kidney Int. Suppl. (2011) 12, 7\u201311 (2011).","journal-title":"Kidney Int. Suppl. (2011)"},{"key":"4674_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","volume":"406","author":"GCKD Collaborators","year":"2025","unstructured":"Collaborators, G. C. K. D. Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 2461\u20132482 (2025).","journal-title":"Lancet"},{"key":"4674_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4674_CR6","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun, H. M. et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat. Med. 30, 2058\u20132066 (2024).","journal-title":"Nat. Med."},{"key":"4674_CR7","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.14443","volume":"23","author":"JFE Mann","year":"2021","unstructured":"Mann, J. F. E. et al. Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diab. Obes. Metab. 23, 2058\u20132066 (2021).","journal-title":"Diab. Obes. Metab."},{"key":"4674_CR8","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2337\/dc23-0261","volume":"46","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink, H. J. L. et al. Effects of tirzepatide versus insulin glargine on cystatin C-based kidney function: a SURPASS-4 post hoc analysis. Diab. Care 46, 1501\u20131506 (2023).","journal-title":"Diab. Care"},{"key":"4674_CR9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/dom.13668","volume":"21","author":"KR Tuttle","year":"2019","unstructured":"Tuttle, K. R. et al. Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). Diab. Obes. Metab. 21, 1493\u20131497 (2019).","journal-title":"Diab. Obes. Metab."},{"key":"4674_CR10","doi-asserted-by":"publisher","first-page":"F443","DOI":"10.1152\/ajprenal.00280.2019","volume":"318","author":"AVR Hviid","year":"2020","unstructured":"Hviid, A. V. R. & S\u00f8rensen, C. M. Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation. Am. J. Physiol. Ren. Physiol. 318, F443\u2013F454 (2020).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"4674_CR11","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke, C. et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155, 1280\u20131290 (2014).","journal-title":"Endocrinology"},{"key":"4674_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","volume":"105","author":"KC Sourris","year":"2024","unstructured":"Sourris, K. C. et al. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation. Kidney Int. 105, 132\u2013149 (2024).","journal-title":"Kidney Int."},{"key":"4674_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1159\/000509418","volume":"144","author":"ME Ougaard","year":"2020","unstructured":"Ougaard, M. E. et al. Liraglutide improves the kidney function in a murine model of chronic kidney disease. Nephron 144, 595\u2013606 (2020).","journal-title":"Nephron"},{"key":"4674_CR14","doi-asserted-by":"publisher","first-page":"e00234","DOI":"10.1002\/edm2.234","volume":"4","author":"KD Bj\u00f8rnholm","year":"2021","unstructured":"Bj\u00f8rnholm, K. D., Ougaard, M. E., Skovsted, G. F., Knudsen, L. B. & Pyke, C. Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree. Endocrinol. Diab. Metab. 4, e00234 (2021).","journal-title":"Endocrinol. Diab. Metab."},{"key":"4674_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000529374","volume":"54","author":"KR Tuttle","year":"2023","unstructured":"Tuttle, K. R. et al. Indicators of kidney fibrosis in patients with type 2 diabetes and chronic kidney disease treated with dulaglutide. Am. J. Nephrol. 54, 74\u201382 (2023).","journal-title":"Am. J. Nephrol."},{"key":"4674_CR16","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/ndt\/gfaf114","volume":"40","author":"DZI Cherney","year":"2025","unstructured":"Cherney, D. Z. I. et al. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol. Dial. Transpl. 40, 2182\u20132192 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"4674_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.kint.2025.10.005","volume":"109","author":"M Pruijm","year":"2026","unstructured":"Pruijm, M. et al. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int. 109, 6\u201316 (2026).","journal-title":"Kidney Int."},{"key":"4674_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."},{"key":"4674_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.5001\/omj.2012.23","volume":"27","author":"WA Mula-Abed","year":"2012","unstructured":"Mula-Abed, W. A., Al Rasadi, K. & Al-Riyami, D. Estimated Glomerular Filtration Rate (eGFR): a serum creatinine-based test for the detection of chronic kidney disease and its impact on clinical practice. Oman Med. J. 27, 108\u2013113 (2012).","journal-title":"Oman Med. J."},{"key":"4674_CR20","unstructured":"National Kidney Foundation. CKD-EPI creatinine equation (2021). National Kidney Foundation https:\/\/www.kidney.org\/professionals\/kdoqi\/gfr_calculator\/formula (2021)."},{"key":"4674_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-023-05769-3","volume":"619","author":"BB Lake","year":"2023","unstructured":"Lake, B. B. et al. An atlas of healthy and injured cell states and niches in the human kidney. Nature 619, 585\u2013594 (2023).","journal-title":"Nature"},{"key":"4674_CR22","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.ajpc.2023.100502","volume":"14","author":"ED Michos","year":"2023","unstructured":"Michos, E. D., Bakris, G. L., Rodbard, H. W. & Tuttle, K. R. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection. Am. J. Prev. Cardiol. 14, 100502 (2023).","journal-title":"Am. J. Prev. Cardiol."},{"key":"4674_CR23","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1161\/HYPERTENSIONAHA.111.175315","volume":"58","author":"MC Foster","year":"2011","unstructured":"Foster, M. C. et al. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension 58, 784\u2013790 (2011).","journal-title":"Hypertension"},{"key":"4674_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10334-019-00773-z","volume":"33","author":"KA Spit","year":"2020","unstructured":"Spit, K. A. et al. Renal sinus fat and renal hemodynamics: a cross-sectional analysis. MAGMA 33, 73\u201380 (2020).","journal-title":"MAGMA"},{"key":"4674_CR25","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.2337\/db20-1031","volume":"70","author":"X Chen","year":"2021","unstructured":"Chen, X. et al. Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes. Diabetes 70, 2322\u20132332 (2021).","journal-title":"Diabetes"},{"key":"4674_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122866","volume":"352","author":"X Qiu","year":"2024","unstructured":"Qiu, X. et al. The role of perirenal adipose tissue deposition in chronic kidney disease progression: mechanisms and therapeutic implications. Life Sci. 352, 122866 (2024).","journal-title":"Life Sci."},{"key":"4674_CR27","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1681\/ASN.2017121260","volume":"29","author":"A Srivastava","year":"2018","unstructured":"Srivastava, A. et al. The prognostic value of histopathologic lesions in native kidney biopsy specimens: results from the Boston Kidney Biopsy Cohort Study. J. Am. Soc. Nephrol. 29, 2213\u20132224 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4674_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1001\/jamacardio.2023.0056","volume":"8","author":"LF Buckley","year":"2023","unstructured":"Buckley, L. F. et al. Associations between kidney histopathologic lesions and incident cardiovascular disease in adults with chronic kidney disease. JAMA Cardiol. 8, 357\u2013365 (2023).","journal-title":"JAMA Cardiol."},{"key":"4674_CR29","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/ijms23031723","volume":"23","author":"R Inagi","year":"2022","unstructured":"Inagi, R. Organelle stress and metabolic derangement in kidney disease. Int. J. Mol. Sci. 23, 1723 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"4674_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114463","volume":"446","author":"X Zhou","year":"2025","unstructured":"Zhou, X. et al. Endoplasmic reticulum stress and unfolded protein response in renal lipid metabolism. Exp. Cell. Res. 446, 114463 (2025).","journal-title":"Exp. Cell. Res."},{"key":"4674_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-023-01501-9","volume":"8","author":"X Di","year":"2023","unstructured":"Di, X. et al. Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets. Signal Transduct. Target Ther. 8, 282 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"4674_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","volume":"7","author":"Q Yuan","year":"2022","unstructured":"Yuan, Q., Tang, B. & Zhang, C. Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduct. Target Ther. 7, 182 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"4674_CR33","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.biopha.2018.02.090","volume":"101","author":"L Chen","year":"2018","unstructured":"Chen, L. et al. Central role of dysregulation of TGF-\u03b2\/Smad in CKD progression and potential targets of its treatment. Biomed. Pharmacother. 101, 670\u2013681 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"4674_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1042\/CS20180438","volume":"133","author":"P Huynh","year":"2019","unstructured":"Huynh, P. & Chai, Z. Transforming growth factor \u03b2 (TGF\u03b2) and related molecules in chronic kidney disease (CKD). Clin. Sci. (Lond.) 133, 287\u2013313 (2019).","journal-title":"Clin. Sci. (Lond.)"},{"key":"4674_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cyto.2016.08.019","volume":"88","author":"G Vega","year":"2016","unstructured":"Vega, G., Alarc\u00f3n, S. & San Mart\u00edn, R. The cellular and signalling alterations conducted by TGF-\u03b2 contributing to renal fibrosis. Cytokine 88, 115\u2013125 (2016).","journal-title":"Cytokine"},{"key":"4674_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.696542","volume":"9","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Signaling pathways involved in diabetic renal fibrosis. Front Cell Dev. Biol. 9, 696542 (2021).","journal-title":"Front Cell Dev. Biol."},{"key":"4674_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cytogfr.2025.05.007","volume":"84","author":"Z Ansari","year":"2025","unstructured":"Ansari, Z. et al. Exploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression. Cytokine Growth Factor Rev. 84, 120\u2013134 (2025).","journal-title":"Cytokine Growth Factor Rev."},{"key":"4674_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejphar.2017.12.016","volume":"820","author":"W Lv","year":"2018","unstructured":"Lv, W., Booz, G. W., Wang, Y., Fan, F. & Roman, R. J. Inflammation and renal fibrosis: recent developments on key signaling molecules as potential therapeutic targets. Eur. J. Pharmacol. 820, 65\u201376 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"4674_CR39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.devcel.2013.08.020","volume":"26","author":"M Giannotta","year":"2013","unstructured":"Giannotta, M., Trani, M. & Dejana, E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev. Cell 26, 441\u2013454 (2013).","journal-title":"Dev. Cell"},{"key":"4674_CR40","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1161\/ATVBAHA.116.307610","volume":"36","author":"N Reglero-Real","year":"2016","unstructured":"Reglero-Real, N., Colom, B., Bodkin, J. V. & Nourshargh, S. Endothelial cell junctional adhesion molecules: role and regulation of expression in inflammation. Arterioscler Thromb. Vasc. Biol. 36, 2048\u20132057 (2016).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"4674_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1161\/ATVBAHA.121.316668","volume":"42","author":"D Liao","year":"2022","unstructured":"Liao, D. et al. Atomic level dissection of the platelet endothelial cell adhesion molecule 1 (PECAM-1) homophilic binding interface: implications for endothelial cell barrier function. Arterioscler Thromb. Vasc. Biol. 42, 193\u2013204 (2022).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"4674_CR42","doi-asserted-by":"publisher","first-page":"20836","DOI":"10.1074\/jbc.M114.557454","volume":"289","author":"H Mei","year":"2014","unstructured":"Mei, H. et al. Regulation of endothelial cell barrier function by antibody-driven affinity modulation of platelet endothelial cell adhesion molecule-1 (PECAM-1). J. Biol. Chem. 289, 20836\u201320844 (2014).","journal-title":"J. Biol. Chem."},{"key":"4674_CR43","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1152\/physrev.00035.2003","volume":"84","author":"G Bazzoni","year":"2004","unstructured":"Bazzoni, G. & Dejana, E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol. Rev. 84, 869\u2013901 (2004).","journal-title":"Physiol. Rev."},{"key":"4674_CR44","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/CIRCRESAHA.122.322332","volume":"132","author":"J Aman","year":"2023","unstructured":"Aman, J. & Margadant, C. Integrin-dependent cell-matrix adhesion in endothelial health and disease. Circ. Res. 132, 355\u2013378 (2023).","journal-title":"Circ. Res."},{"key":"4674_CR45","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1681\/ASN.2021101319","volume":"33","author":"M Rogg","year":"2022","unstructured":"Rogg, M. et al. \u03b1-Parvin defines a specific integrin adhesome to maintain the glomerular filtration barrier. J. Am. Soc. Nephrol. 33, 786\u2013808 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4674_CR46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nrneph.2012.291","volume":"9","author":"N Sachs","year":"2013","unstructured":"Sachs, N. & Sonnenberg, A. Cell-matrix adhesion of podocytes in physiology and disease. Nat. Rev. Nephrol. 9, 200\u2013210 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"4674_CR47","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4674_CR48","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4674_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve, S. V. et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diab. Endocrinol. 13, 15\u201328 (2025).","journal-title":"Lancet Diab. Endocrinol."},{"key":"4674_CR50","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc24-1533","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee, M. M. Y. et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 Diabetes: a systematic review and meta-analysis of randomized trials. Diab. Care 48, 846\u2013859 (2025).","journal-title":"Diab. Care"},{"key":"4674_CR51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo, E. M. et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diab. Endocrinol. 12, 545\u2013557 (2024).","journal-title":"Lancet Diab. Endocrinol."},{"key":"4674_CR52","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen, B. L. et al. Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation 150, 1781\u20131790 (2024).","journal-title":"Circulation"},{"key":"4674_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf032","volume":"18","author":"A Huber","year":"2025","unstructured":"Huber, A. et al. T1 mapping magnetic resonance imaging predicts decline of kidney function. Clin. Kidney J. 18, sfaf032 (2025).","journal-title":"Clin. Kidney J."},{"key":"4674_CR54","doi-asserted-by":"publisher","first-page":"ii41","DOI":"10.1093\/ndt\/gfy198","volume":"33","author":"M Wolf","year":"2018","unstructured":"Wolf, M. et al. Magnetic resonance imaging T1- and T2-mapping to assess renal structure and function: a systematic review and statement paper. Nephrol. Dial. Transpl. 33, ii41\u2013ii50 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"4674_CR55","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/jmri.20043","volume":"19","author":"LP Li","year":"2004","unstructured":"Li, L. P. et al. Evaluation of the reproducibility of intrarenal R2* and DeltaR2* measurements following administration of furosemide and during waterload. J. Magn. Reson. Imaging 19, 610\u2013616 (2004).","journal-title":"J. Magn. Reson. Imaging"},{"key":"4674_CR56","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/jmri.24446","volume":"40","author":"DS Khatir","year":"2014","unstructured":"Khatir, D. S., Pedersen, M., Jespersen, B. & Buus, N. H. Reproducibility of MRI renal artery blood flow and BOLD measurements in patients with chronic kidney disease and healthy controls. J. Magn. Reson. Imaging 40, 1091\u20131098 (2014).","journal-title":"J. Magn. Reson. Imaging"},{"key":"4674_CR57","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2215\/CJN.13201019","volume":"15","author":"A Srivastava","year":"2020","unstructured":"Srivastava, A. et al. Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD. Clin. J. Am. Soc. Nephrol. 15, 776\u2013783 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"4674_CR58","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1159\/000512854","volume":"51","author":"LP Li","year":"2020","unstructured":"Li, L. P. et al. Medullary blood oxygen level-dependent MRI index (R2*) is associated with annual loss of kidney function in moderate CKD. Am. J. Nephrol. 51, 966\u2013974 (2020).","journal-title":"Am. J. Nephrol."},{"key":"4674_CR59","first-page":"667","volume":"7","author":"M Pruijm","year":"2016","unstructured":"Pruijm, M., Milani, B. & Burnier, M. Blood oxygenation level-dependent MRI to assess renal oxygenation in renal diseases: progresses and challenges. Front Physiol. 7, 667 (2016).","journal-title":"Front Physiol."},{"key":"4674_CR60","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/IJNRD.S42924","volume":"7","author":"J Neugarten","year":"2014","unstructured":"Neugarten, J. & Golestaneh, L. Blood oxygenation level-dependent MRI for assessment of renal oxygenation. Int. J. Nephrol. Renovasc Dis. 7, 421\u2013435 (2014).","journal-title":"Int. J. Nephrol. Renovasc Dis."},{"key":"4674_CR61","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.ekir.2023.02.1092","volume":"8","author":"PV Prasad","year":"2023","unstructured":"Prasad, P. V., Li, L. P., Hack, B., Leloudas, N. & Sprague, S. M. Quantitative blood oxygenation level dependent magnetic resonance imaging for estimating intra-renal oxygen availability demonstrates kidneys are hypoxemic in human CKD. Kidney Int. Rep. 8, 1057\u20131067 (2023).","journal-title":"Kidney Int. Rep."},{"key":"4674_CR62","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2215\/CJN.0000000979","volume":"21","author":"T McDonnell","year":"2026","unstructured":"McDonnell, T. et al. Sex-associated biomarker differences in CKD progression and mortality. Clin. J. Am. Soc. Nephrol. 21, 765\u2013774 (2026).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"4674_CR63","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2215\/CJN.0000000642","volume":"20","author":"SA van Eeghen","year":"2024","unstructured":"van Eeghen, S. A. et al. Unraveling sex differences in kidney health and CKD: a review of the effect of sex hormones. Clin. J. Am. Soc. Nephrol. 20, 301\u2013310 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"4674_CR64","doi-asserted-by":"publisher","first-page":"e198545","DOI":"10.1172\/JCI198545","volume":"136","author":"AS Naik","year":"2026","unstructured":"Naik, A. S. et al. Metabolic surgery mitigates early kidney injury in obese youth with diabetes by suppressing mTORC1\/JAK\/STAT signaling. J. Clin. Invest. 136, e198545 (2026).","journal-title":"J. Clin. Invest."},{"key":"4674_CR65","doi-asserted-by":"publisher","first-page":"ii4","DOI":"10.1093\/ndt\/gfy152","volume":"33","author":"NM Selby","year":"2018","unstructured":"Selby, N. M. et al. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrol. Dial. Transpl. 33 ii4\u2013ii14 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"4674_CR66","doi-asserted-by":"crossref","unstructured":"Zaratiegui, A. et al. GxP Single-cell RNA-seq and Spatial Transcriptomics end-to-end pipeline for clinical research. Comput. Struct. Biotechnol. J. 35 https:\/\/doi.org\/10.34133\/csbj.0164 (2026).","DOI":"10.34133\/csbj.0164"},{"key":"4674_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37126-3","volume":"14","author":"HCT Nguyen","year":"2023","unstructured":"Nguyen, H. C. T., Baik, B., Yoon, S., Park, T. & Nam, D. Benchmarking integration of single-cell differential expression. Nat. Commun. 14, 1570 (2023).","journal-title":"Nat. Commun."},{"key":"4674_CR68","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/1471-2105-6-225","volume":"6","author":"J Tomfohr","year":"2005","unstructured":"Tomfohr, J., Lu, J. & Kepler, T. B. Pathway level analysis of gene expression using singular value decomposition. BMC Bioinf. 6, 225 (2005).","journal-title":"BMC Bioinf."},{"key":"4674_CR69","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2025","unstructured":"Jin, S., Plikus, M. V. & Nie, Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat. Protoc. 20, 180\u2013219 (2025).","journal-title":"Nat. Protoc."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04674-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04674-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04674-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:02:43Z","timestamp":1790845363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04674-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":69,"alternative-id":["4674"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04674-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.R.T. is supported by United States federal research grants from the NIDDK NHLBI, NCATS, NIMHD and the NIH Director\u2019s Office as well as the CDC. She has also received investigator-initiated grant support from Travere, Bayer, Otsuka, Doris Duke Charitable Foundation, Benaroya Research Institute and Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation). She reports consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Glaxo Smith Kline, Novo Nordisk, Bayer, ProKidney, Alnylam, Otsuka and Roche as well as speaker fees from Novo Nordisk, Bayer, Boehringer Ingelheim, AstraZeneca and Travere. Additionally, she reports being chair of data safety monitoring boards for the National Institute of Diabetes and Digestive and Kidney Disease and George Clinical Institute and member of the data safety monitoring board for AstraZeneca. She reports leadership roles as chair for the Diabetic Kidney Disease Collaborative and chair for Kidney Week 2025 Program Committee, both for the American Society of Nephrology. P.B. declares grants and contracts through the University of Washington and Seattle Children\u2019s Research Institute from the National Institutes of Health (NIH) and Breakthrough T1D. P.B. declares serving or having served as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, LG Chemistry, Sanofi, Sidera Bio, Merck, Novo Nordisk, Roche and Horizon Pharma. P.B. also serves or has served on the advisory boards and\/or steering committees of AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly Novo Nordisk, Sanofi, Sidera Bio, Roche and XORTX. P.B. serves as DMC Chair for Bayer. P.B. reports grant funding from AstraZeneca, Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Merck and Amgen\/Horizon Pharma. M.P. declares he is member of advisory boards at Vifor, GSK, Boehringer Ingelheim, Baxter, Novo Nordisk and Bayer, has been a speaker for AstraZeneca, Astellas, Vifor, Baxter and Braun and has received investigator-initiated grant support from Nephrospec. J.B.H. declares he is a consultant at Sygnamap. D.Z.I.C. declares honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, AMGEN, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, GSK, Biobridge, Vantage, Altimmune and Novo Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, Lexicon, Novo Nordisk and Bayer. N.B. is an employee of and owns shares in Novo Nordisk. M.M.C. is an employee of and owns shares in Novo Nordisk. V.D. is an employee of and owns shares in Novo Nordisk. T.I. is a former employee of and owns shares in Novo Nordisk. T.P.G. is an employee of and owns shares in Novo Nordisk. P.A.S. is an employee of and owns shares in Novo Nordisk. A.Z. is an employee of and owns shares in Novo Nordisk. M.K. declares grants and contracts through the University of Michigan from the National Institutes of Health (NIH) and Novo Nordisk in support of this work and outside of this work from Chan Zuckerberg Initiative, AstraZeneca, Apellis, Bayer, Eli Lilly, Boehringer Ingelheim, European Union Innovative Medicine Initiative, Certa Therapeutics, RenalytixAI, Regeneron, Sanofi, Dimerix, Travere and Vera Therapeutics. M.K. has received consulting fees through the University of Michigan from Novo Nordisk, Alexion, Novartis, Roche Diagnostics and Vera Therapeutics. In addition, M.K. has a patent PCT\/EP2014\/073413 \u2018Biomarkers and methods for progression prediction for chronic kidney disease\u2019 licensed.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}